Australia markets close in 4 hours 56 minutes

Karuna Therapeutics, Inc. (KRTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
124.52+0.51 (+0.41%)
At close: 4:00PM EDT
124.07 -0.45 (-0.36%)
After hours: 05:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close124.01
Open124.29
Bid123.95 x 1000
Ask145.00 x 1000
Day's range124.04 - 128.49
52-week range74.06 - 146.97
Volume60,020
Avg. volume127,686
Market cap3.68B
Beta (5Y monthly)1.80
PE ratio (TTM)N/A
EPS (TTM)-3.89
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est158.60
  • Business Wire

    Karuna Therapeutics to Present at 2021 Virtual Wells Fargo Healthcare Conference

    BOSTON, September 01, 2021--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in a fireside chat at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 8:40 a.m. ET.

  • Business Wire

    Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference

    BOSTON, August 31, 2021--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will participate in a panel titled "Emerging Therapies for Psychiatric Disorders" at the Citi 16th Annual BioPharma Virtual Conference on September 8, 2021, at 10:40 a.m. ET.

  • Business Wire

    Karuna Therapeutics Reports Second Quarter 2021 Financial Results and Provides General Business Update

    BOSTON, August 05, 2021--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2021 and provided a general business update.